| Biomarker ID | 286 |
| PMID | 18550118 |
| Year | 2008 |
| Biomarker | %fPSA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-ID regulation of gene expression,Prostate cancer,Androgen receptor proteolysis and transcription regulation,Androgen receptor signaling, proteolysis, and transcription regulation,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer Vs No Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 123 men were taken into the study out of which 63 (51%) were cancer cases and 60 (49%) were non cancer controls |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.61 (95% CI: 0.51-0.71) |
| Accuracy | NA |
| Level Of Significance | p=0.008 |
| Method Used | dual monoclonal sandwich assays |
| Clinical | No |
| Remarks | fPSA is defined as fPSA/PSA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |